MechanismIndicationDiscoveryPreclinicalPhase 1Phase 2Phase 3Ownership
PIPE-791
LPA1R Antagonist IPF*
 
Wholly-owned
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). We are currently conducting a Phase 1 clinical trial of PIPE-791 in healthy volunteers for the potential treatment of IPF. Thereafter, we plan to commence Phase 1b open-label trials in each of IPF and Progressive MS to measure lung and brain receptor occupancy, respectively, by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.
close x
LPA1R Antagonist PPMS/SPMS*
 
Wholly-owned
Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). We are currently conducting a Phase 1 clinical trial of PIPE-791 in healthy volunteers for the potential treatment of IPF. Thereafter, we plan to commence Phase 1b open-label trials in each of IPF and Progressive MS to measure lung and brain receptor occupancy, respectively, by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.
close x
PIPE-307
M1R Antagonist RRMS
 
In Collaboration with Johnson & Johnson
PIPE-307 is a novel, small molecule, selective inhibitor of the muscarinic type 1 M1 receptor (M1R), in development for relapse-remitting multiple sclerosis (RRMS) and depression. We have completed two Phase 1 trials of PIPE-307 in healthy volunteers. We have initiated a Phase 2 trial of PIPE-307 for the potential treatment of RRMS. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines (J&J).
close x
M1R Antagonist Depression
 
In Collaboration with Johnson & Johnson
PIPE-307 is a novel, small molecule, selective inhibitor of the muscarinic type 1 M1 receptor (M1R), in development for relapse-remitting multiple sclerosis (RRMS) and depression. We have completed two Phase 1 trials of PIPE-307 in healthy volunteers. We have initiated a Phase 2 trial of PIPE-307 for the potential treatment of RRMS. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines (J&J).
close x
LPA1R Antagonist

IPF*

DiscoveryPreclinicalPhase 1Phase 2Phase 3

Wholly-owned

 
LPA1R Antagonist

PPMS/SPMS*

DiscoveryPreclinicalPhase 1Phase 2Phase 3

Wholly-owned

 
M1R Antagonist

RRMS

DiscoveryPreclinicalPhase 1Phase 2Phase 3

In Collaboration with Johnson & Johnson

 
M1R Antagonist

Depression

DiscoveryPreclinicalPhase 1Phase 2Phase 3

In Collaboration with Johnson & Johnson

 

* Partnered
**Wholly-owned

LPA1R Antagonist

Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). We are currently conducting a Phase 1 clinical trial of PIPE-791 in healthy volunteers for the potential treatment of IPF. Thereafter, we plan to commence Phase 1b open-label trials in each of IPF and Progressive MS to measure lung and brain receptor occupancy, respectively, by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.

LPA1R Antagonist

Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). We are currently conducting a Phase 1 clinical trial of PIPE-791 in healthy volunteers for the potential treatment of IPF. Thereafter, we plan to commence Phase 1b open-label trials in each of IPF and Progressive MS to measure lung and brain receptor occupancy, respectively, by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.

M1R Antagonist

PIPE-307 is a novel, small molecule, selective inhibitor of the muscarinic type 1 M1 receptor (M1R), in development for relapse-remitting multiple sclerosis (RRMS) and depression. We have completed two Phase 1 trials of PIPE-307 in healthy volunteers. We have initiated a Phase 2 trial of PIPE-307 for the potential treatment of RRMS. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines (J&J).

M1R Antagonist

PIPE-307 is a novel, small molecule, selective inhibitor of the muscarinic type 1 M1 receptor (M1R), in development for relapse-remitting multiple sclerosis (RRMS) and depression. We have completed two Phase 1 trials of PIPE-307 in healthy volunteers. We have initiated a Phase 2 trial of PIPE-307 for the potential treatment of RRMS. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines (J&J).

Contineum Pipeline

* Single Phase 1 clinical trial of PIPE-791 for the potential treatment of IPF and Progressive MS.

PIPE-791

Our wholly-owned lead asset, PIPE-791, is a novel, brain penetrant, small molecule antagonist of the lysophosphatidic acid 1 receptor (LPA1R) in development for the potential treatment of idiopathic pulmonary fibrosis (IPF) and progressive multiple sclerosis (Progressive MS). We are currently conducting a Phase 1 clinical trial of PIPE-791 in healthy volunteers for the potential treatment of IPF. Thereafter, we plan to commence Phase 1b open-label trials in each of IPF and Progressive MS to measure lung and brain receptor occupancy, respectively, by positron emission tomography (PET) imaging, which will inform dose selection for future clinical development in Phase 2a trials.

LPAIR DC

We are also developing a peripherally-restricted LPA1R antagonist to further expand clinical indications involving LPA1R antagonism. We nominated a development candidate, LPAR1 DC, in December 2023.

PIPE-307

PIPE-307 is a novel, small molecule, selective inhibitor of the muscarinic type 1 M1 receptor (M1R), in development for relapse-remitting multiple sclerosis (RRMS) and depression. We have completed two Phase 1 trials of PIPE-307 in healthy volunteers. We have initiated a Phase 2 trial of PIPE-307 for the potential treatment of RRMS. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines (J&J).